Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

Effect of dimethyl fumarate on lymphocytes in RRMS

(2019) Devangi Mehta et al.   NEUROLOGY

Nonclassical Monocytes in Health and Disease

(2019) Prakash Babu Narasimhan et al.   Annual Review of Immunology

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes

(2019) Karl E. Carlström et al.   Nature Communications

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients

(2019) Jan W. Traub et al.   Journal of Neuroinflammation

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

(2019) Fabian Sierra Morales et al.   JOURNAL OF NEUROLOGY

IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis

(2019) Christina Lückel et al.   Nature Communications

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity

(2018) Michael D. Kornberg et al.   SCIENCE

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)

(2018) Stanley L. Cohan et al.   Multiple Sclerosis and Related Disorders

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis

(2018) Elizabeth A. Mills et al.   Frontiers in Neurology

Subsets of activated monocytes and markers of inflammation in incipient and progressed multiple sclerosis

(2017) Mikkel Carstensen Gjelstrup et al.   IMMUNOLOGY AND CELL BIOLOGY

Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients

(2017) Qi Wu et al.   JOURNAL OF IMMUNOLOGY

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile

(2017) Silvia Medina et al.   Multiple Sclerosis Journal

Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count

(2017) Erin E Longbrake et al.   Multiple Sclerosis Journal

Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile

(2017) Silvia Medina et al.   Multiple Sclerosis Journal

Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count

(2017) Erin E Longbrake et al.   Multiple Sclerosis Journal

Dimethyl fumarate alters B-cell memory and cytokine production in MS patients

(2017) Matthew D. Smith et al.   Annals of Clinical and Translational Neurology

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis

(2016) Rui Li et al.   JOURNAL OF IMMUNOLOGY

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

(2016) Ulf Schulze-Topphoff et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature

(2016) Elena Grebenciucova et al.   Multiple Sclerosis and Related Disorders

Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination

(2016) Richard B. Kennedy et al.   Frontiers in Immunology

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

(2015) Erin E Longbrake et al.   Multiple Sclerosis Journal

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients

(2015) Erin E Longbrake et al.   Multiple Sclerosis Journal

Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study

(2014) Henning K Olberg et al.   Multiple Sclerosis Journal

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort

(2013) O. Outteryck et al.   EUROPEAN JOURNAL OF NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Structure and function of immunoglobulins

(2010) Harry W. Schroeder et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY